The FDA has granted approval for Lipfendra, the first oral PCSK9 inhibitor designed to treat high cholesterol, particularly familial hypercholesterolemia. This new medication offers a non-invasive option for patients and is intended to be used alongside dietary changes and exerc…
The FDA has approved Lipfendra (enlicitide), marking the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for adults with high cholesterol. This approval…
The FDA has approved Lipfendra (enlicitide), the first oral therapy to inhibit PCSK9, aimed at reducing low-density lipoprotein cholesterol (LDL-C) in adults with high cholesterol…
The FDA has granted priority review to Lipfendra, the first oral medication designed to block the PCSK9 protein, which is crucial in regulating LDL cholesterol levels. This develo…
Recent viral claims suggest that statins, commonly prescribed cholesterol-lowering medications, may contribute to dementia. However, scientific evidence reviewed by DW Fact Check…
The FDA has approved Lipfendra, a groundbreaking pill from Merck designed to significantly lower cholesterol levels in patients at high risk of heart disease. This noninjectable m…
The FDA has approved Lipfendra, the first once-daily oral PCSK9 inhibitor, which can reduce LDL cholesterol levels by 56% to 60% when used alongside statins. Developed by Merck, t…
This article addresses prevalent myths surrounding high cholesterol management, emphasizing the importance of understanding cholesterol types and dietary impacts. It clarifies mis…
CKM syndrome, recently defined by the American Heart Association, affects approximately 90 percent of U.S. adults, many of whom are unaware of it. This syndrome encompasses a rang…
A pharmacist has identified five types of tea that may support individuals in managing high cholesterol levels. The recommended teas include green tea, oolong tea, hibiscus tea, m…
As CBS's iconic news program '60 Minutes' gears up for its next season, it faces a unique challenge of integrating pharmaceutical sponsorships into its traditionally hard-hitting…